Daniel Vitt

This inventor holds 14 USPTO granted patents and 14 published patent applications, plus 3 CIPO patents and 7 EPO patents. Top assignees: Immunic Ag, 4Sc Ag, 4Sc Mg. Active years: 2004-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Daniel Vitt. Retrieved from https://idiyas.com/inventor/daniel-vitt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 14)

% Patents Active = 92.9

CIPO Patents = 3 (Patent Applications = 11)

EPO Patents = 7 (Patent Applications = 21)

Average Co-Inventor Count = 4.1

ph-index = 4

Forward Citations = 37(Granted Patents)

Location History:

Planegg-Martinsried, DE (2004)
Germering, DE (2012 - 2024)

Company Filing History:

Years Active: 2004-2026

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12629347 - Compounds and dosage regimen for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases (2026-05-19),

2. 12433860 - Treatment of multiple sclerosis comprising DHODH inhibitors (2025-10-07),

3. 12167994 - Vidofludimus for use in the treatment or prevention of viral diseases (2024-12-17),

4. 12037305 - Calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferative agents (2024-07-16),

5. 11877995 - Compounds and dosage regimen for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases (2024-01-23),

6. 11877994 - Treatment of multiple sclerosis comprising DHODH inhibitors (2024-01-23),

7. 11376232 - Vidofludimus for use in the treatment or prevention of viral diseases (2022-07-05),

8. 11292788 - IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation (2022-04-05),

9. 10633369 - Method of inhibiting DYRK1B (2020-04-28),

10. 9951050 - Method of inhibiting DYRK1B (2018-04-24),

11. 8653138 - Calcium salts of compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents (2014-02-18),

12. 8354433 - Anti-inflammatory agents as virostatic compounds (2013-01-15),

13. 8207174 - Aryloxypropanolamines, methods of preparation therof and use of aryloxypropanolamines as medicaments (2012-06-26),

14. 6727100 - Method of identifying candidate molecules (2004-04-27),

Title: **The Innovative Journey of Daniel Vitt**

Introduction

Daniel Vitt, a distinguished inventor located in Germering, Germany, has made significant contributions to the field of pharmaceutical innovation. With 12 patents to his name, he has been at the forefront of research aimed at combating viral diseases and addressing inflammatory responses.

Latest Patents

Among his noteworthy inventions, Daniel's recent patents stand out for their potential impact on global health. One of his latest innovations is the patent for **Vidofludimus**, which is designed for the treatment and prevention of viral diseases. This compound specifically inhibits dihydroorotate dehydrogenase (DHODH), proving to be especially relevant for combating infections caused by various coronaviruses, including SARS-CoV-2 and its mutated versions.

Another significant patent involves the development of **calcium salt polymorphs** that serve as anti-inflammatory, immunomodulatory, and anti-proliferative agents. This invention highlights the creation of a unique white crystalline polymorph A of the calcium salt of a compound that inhibits DHODH. Its distinct structure can be characterized by an X-ray powder diffraction pattern with specified peaks, underscoring its innovative composition aimed at treating ailments linked to DHODH inhibition.

Career Highlights

Throughout his career, Daniel has worked with notable companies such as Immunic AG and 4SC AG, where he has played a pivotal role in advancing pharmaceutical research. His expertise in the field is not only reflected in his patents but also in his impact on the organizations he has been a part of.

Collaborations

Collaboration has been key to Daniel's success. He has worked closely with talented individuals such as Hella Kohlhof and Andreas Mühler, contributing to the richness and diversity of ideas that drive innovation. These collaborations foster a dynamic environment where creativity and expertise merge to bring transformative inventions to life.

Conclusion

Daniel Vitt stands as a prominent figure in the realm of innovation, particularly in the pharmaceutical sector. His advancements in treatment protocols, particularly targeting viral infections and inflammatory processes, underline the importance of his work. As he continues to innovate and collaborate, his contributions will undoubtedly shape the future of medicine.

Profile summary based on public USPTO records.